Topical immunoglobulins for epithelial herpes simplex keratitis.
A new immunoglobulin preparation for topical administration in the eye has been developed. The tolerance to this preparation was tested in a phase I/II study, in combination with the antiviral drug trifluorothymidine, in 5 patients with untreated episodes of herpes simplex epithelial keratitis. The clinical course of these patients was within usual limits, with a mean healing time of 6.6 days (range 2-15 days). No undesirable effects were observed. Our findings suggest that this new treatment modality is safe and offers a new perspective, but additional studies are required to determine its efficacy.
Kläger
A J
AJ
University Eye Hospital, Basel, Switzerland.
Büchi
E R
ER
Osusky
R
R
Burek-Kozlowska
A
A
Morell
A
A
D000328:Adult; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage* / Q000627:therapeutic use; D016849:Keratitis, Herpetic / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D014271:Trifluridine / Q000627:therapeutic use
D007136:Immunoglobulins; D009883:Ophthalmic Solutions; D014271:Trifluridine